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ABSTRACT 
 The aim of the present investigation was to developoral controlled release matrix tablet 
formulations of Finasteride with different polymer ratios. Finasteride is chemically considered a 
synthetic 4-azasteroid drug. The granules were evaluated for angle of repose, bulk density and 
Compressibility index before being punched as tablets. The tablets were subjected to weight 
variation test, drug content, hardness, friability, and in vitro release studies. Observations of all 
formulations for physical characterization had shown that, all of them comply with the 
specifications of official pharmacopoeias and/or standard references. Different models for kinetic 
study were applied like zero order, first order, Higuchi, HixsonCrowell and Korsmeyer to study 
the release pattern and mechanism. 
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 INTRODUCTION 
Sustained release systems drug delivery system achieves slow release of drug over an extended 
period of time. It provide an immediate dose required for the normal therapeutic response, 
followed by the gradual release of drug in amounts sufficient to maintainthe therapeutic response 
for a specific extended period of time
1
. Sustained release of drugs in gastrointestinal tract 
followed by oral administration is not affected by the absorption process and, it provides blood 
levels that are devoid of the peak and valley effect which are characteristics of the conventional 
intermittent dosage regimen
2
.  
Matrix is defined as a well-mixed composite of one or more drugs with gelling agent i.e. 
hydrophilic polymers. In matrix system of sustained release drug is dispersed homogenously 
throughout a polymeric matrix
3
. It includes coating and pelletization during manufacturing and 
rate of drug release from the dosage form is controlled mainly by the typeand proportion of 
polymer used in the preparations.  
Advantages of matrix tablets are
4, 5, 6, 7
:  
1. Easy to fabricate in different shape and size. High level of reproducibility 
2. Suitable for both non degradable and degradable system.  
3. No dose dumping.  
4. Effective, stable and economical.  
5. Suitable for drugs having high molecular weight.  
Finasteride is chemically considered a synthetic 4-azasteroid drug
8
. It is an enzyme inhibiting 
agent. It is used in the treatment of anti-hyperplasia and also used as anti-baldness agent.  
The mechanism of action of Finasteride is based on its preferential inhibition of Type II 5a-
reductase by formation of a stable complex with the enzyme. This enzyme converts testosterone 
to dihydrotestosterone (DHT), which is a more potent androgenic hormone. Inhibition of Type II 
5a-reductase blocks the peripheral conversion of testosterone to DHT
9
. Significant decrease in 
serum and tissue DHT concentrations, increase in serum testosterone concentrations, and 
substantial increases in prostatic testosterone concentrations. Thedrug is an effective therapeutic 
 agent in the treatment of benign prostatic hyperplasia. Inhibition of the enzyme 5 alpha-reductase 
is believed to be the mechanism of action of this drug
10
. An increase in the level of DHT in the 
prostate results in prostate hyperplasia and urinary tract obstruction. The drug is practically 
insoluble in water, with a mean bioavailability of 63%
11
. 
In present study matrix type tablets of Finasteride were prepared to improve the bioavailability of 
it. 
MATERIAL AND METHOD: 
Finasteride was a gift sample from Fidson healthcare. Eudragit RS-100 was obtained from 
Neimeth, and HPMC from Zolon healthcare. All other chemicals used were of analytical grade. 
 Preparation of tablets  
The granules prepared by wet granulation of drug, filler and hydrophilic polymers were 
compressed into flat faced tablets using by using KBr press. The diameter of the die was 12mm 
and the batch size prepared for each formulation was of 20 tablets. 
                        Table 1: Composition of matrix type tablets of Finasteride 
Ingredients 
       (mg) 
Formulation Code 
MT1 MT2 MT3 MT4  MT5 
Finasteride 80 80 80 80 80 
HPMC 100 100 100 100 100 
EC - 100 100 - - 
Eudragit RS 100 - - 100 100 100 
Ethanol qs qs qs qs qs 
Magnesium stearate 4 4 4 4 4 
Dicalcium phosphate 90 90 90 90 90 
Talc 5 5 5 5 5 
 
Evaluation of Granules 
1. Angle of repose
12 
The angle of repose of prepared granules was determined by the funnel method. The accurately 
weighed granules were taken in a funnel. The granuleswere allowed to flow through the funnel 
freely onto the surface. The diameter of the powder cone was measured and angle of repose was 
calculated using the following equation:  
tan θ= h/r   
Where, h and r are the height and radius of the powder cone. 
2. Bulk and tapped density
13 
A quantity of 2 g of powder from each formula, previously lightly shaken to break any 
agglomerates formed, was introduced into a 10ml measuring cylinder. After the initial volume 
was observed, the cylinder was allowed to fall under its ownweight onto a hard surface from the 
height of 2.5 cm at 2 second intervals. The tapping was continued until no further change in 
volume was noted.  
Bulk density= (Mass of the powder)/(Volume of the bulk powder) 
 
Tapped density= (Mass of the powder)/(Tapped volume of the powder) 
3. Carr’s compressibility index14 
The Carr’s compressibility Index was calculated from Bulk density and tapped density of the 
granules. A quantity of 2g of granules from each formulation, filled into a 10 ml of measuring 
cylinder. Initial bulk volume was measured, and cylinder wasallowed to tap from the height of 
 2.5 cm. The tapped frequency was 25± 2 per min to measure the tapped volume of the granules. 
The bulk density and tapped density were calculated by using the bulk volume and tapped 
volume.  
Carr’s index (%)=(Tapped density-Bulk density)/(Tapped density)  X100 
 
4. Hausner’s ratio15  
Hausner ratio (Hr) is an indirect index of ease of powder flow. It is calculated by the following 
formula:  
Hausner^' s ratio= (Tapped density)/(TaBulk density)   
5. Drug content
16 
An accurately weighed amount of powdered Finasteride granules (100 mg) was extracted with 
water and the solution was filtered through 0.45μ membrane.The absorbance was measured at 
254 nm after suitable dilution. 
Table 2: Evaluation parameters of granules 
Formulation 
code 
Bulk density Tapped density Carr’s 
index 
Hausner’s 
ratio  
 
Angle of 
repose (θ) 
MT1 0.304 0.358 12.5  39O 6' 
MT2 0.392 0.384 13.41  38O 4' 
MT3 0.341 0.427 14.52  37O 9' 
MT4 0.322 0.403 15.6  37O 6' 
MT5 0.298 0.358 16.5  35O 2' 
 
Evaluation of tablets  
1. Thickness and diameter
17
  
Thickness and diameter of tablets was determined using Vernier caliper. Five tablets from each 
batch were used, and average values were calculated.  
 
 
2. Weight variation test
18
  
  Twenty tablets were selected randomly from each batch were weighed individually  and 
together using an electronic balance. The average weight was noted and standard deviation 
calculated. The tablet passes the test if not more than two tablets fall outside the percentage limit 
and none of the tablet differs by more than double the percentage limit. 
% Deviation=(Average weight-Individual weight)/(Individual weight)  X 100 
3. Drug content
19
 
Five tablets were weighed individually and triturated. Powder equivalent to the average weight 
of the tablet was weighed and drug was extracted in water for 6 hours. The solution was filtered 
through 0.45μ membrane. The absorbance was measured at 254 nm after suitable dilution.  
4. Hardness
20
  
For each formulation, the hardness of 6 tablets were determined using the Monsanto hardness 
tester. The tablet was held along its oblong axis in betweenthe two jaws of the tester. At this 
point, reading should be zero kg/cm
2
. Then constant force was applied by rotating the knob until 
the tablet fractured. The value at this point was noted in kg/cm
2
. Generally, a minimum of 4 
kg/cm
2
 hardness is considered acceptable for uncoated tablets.  
5. Friability
21
  
 For each formulation, the friability of 6 tablets was determined using the Roche friabilator. This 
test subjects a number of tablets to the combined effect of shock abrasion by utilizing a plastic 
chamber which revolves at a speed of 25 rpm, dropping the tablets to a distance of 6 inches in 
each revolution. A sample of pre weighed 6 tablets was placed in Rochefriabilator which was 
then operated for 100 revolutions i.e. 4 minutes. The tablets were then dusted and reweighed. A 
loss of less than 1 % in weight in generally considered acceptable.  
% Friability=(Initial weight-Final weight)/(Final weight)  X100 
6. In vitro release studies
22
  
In vitro drug release study for the prepared matrix tablets were conducted for period of 8 hours 
using a six station USP XXVI type II (paddle) apparatus at 37 ± 0.5
0
C and 50 rpm speed. The 
dissolution studies were carried out in triplicate for 10 hours in phosphate buffer of pH 6.8 under 
sink condition. At first half an hour and then every 1- hour interval samples of 5 ml were 
withdrawn from dissolution medium and replaced with fresh medium to maintain the volume 
constant. After filtration and appropriate dilution, the sample solutionwas analyzed at 254 nm for 
Finasteride by a UV- spectrophotometer. The amounts of drug present in the samples were 
calculated with the help of appropriate calibration curve constructed from reference standard. 
Table 3- Evaluation parameters of Finasteride tablets 
Formulation 
code 
Hardness Thickness % Friability % Weight 
variation 
% Drug 
content 
MT1 4.4± 0.21 2.25± 0.04 0.73± 0.05 2.63± 0.05 96.32± 0.08 
MT2 4.5± 0.14 2.37± 0.11 0.71± 0.08 2.84± 0.06 97.53± 0.15 
MT3 4.1± 0.09 2.18± 0.06 0.78± 0.09 3.22± 0.11 98.43± 0.16 
MT4 4.6± 0.15 2.43± 0.15 0.70± 0.04 3.12± 0.09 99.11± 0.05 
MT5 4.8± 0.22 2.32± 0.07 0.81± 0.03 2.93± 0.08 99.65± 0.06 
 
 
Fig-1: In-vitro drug release profile of Finasteride tablets. 
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 Table 4- Dissolution profile of Finasteride tablets. 
Formulation 
code 
Zero order First order Higuchi Korsemeyer-
peppas 
Hixon 
crowell 
MT1 0.8350 0.9215 0.9562 0.9892 
n=0.3942 
0.9452 
MT2 0.9108 0.9558 0.9845 0.9926 
n= 0.5214 
0.9832 
MT3 0.9217 0.9315 0.9915 0.9946 
n=0.6011 
0.9915 
MT4 0.8864 0.9011 0.9965 0.9921 
n=0.5246 
0.9924 
MT5 0.8075 0.9295 0.9872 0.988847 
n=0.5642 
0.9835 
 
 
 
RESULTS AND DISCUSSION 
The current investigation deals with the optimization of sustained release matrix tablets of 
Finasteride using different polymers. Polymers used were HPMC, Ethyl cellulose and Eudragit 
RS100. 
All the formulations showed uniform thickness. In a weightvariation test, the pharmacopoeial 
limit for percentage deviation for the tablets of more than 250 mg is ± 5%.The average 
percentage deviation of all the tablet formulations was found to be within the above limit, and 
hence all the formulations passed the test for uniformity of weight as per the official 
requirements.  
Satisfactory uniformity in drug content was found among different batches of tablets, and 
percentage of drug content was more than 96 %. The formulation MT5 showed a comparatively 
high hardness value of 4.8±0.22 kg/cm
2
.  
This could be due to the presence of more ethylcellulose which is generally responsible for more 
hardness of the tablet.  
In the present study the percentage friability for all theformulations was below 1% indicating that 
the friability is within the prescribed limits.  
All the tablet formulations showed acceptable pharmacotechnical properties and complied with 
the in-house specifications for weight variation, drug content, hardness and friability.  
The release of drug mainly depend upon the polymer concentration. Matrix tablets of batch MT1 
shows maximum release 86.42%  in 10 hrs. The quick release was observed in tablets containing 
ethylcellulose, it may be due to high solubility of EC at pH 6.8. This polymer characteristic gives 
to the matrix a quick gel erosion rate and a high erosion degree of the overall system. 
The in vitro release data was applied to various kinetic models to predict the drug release kinetic 
mechanism. Nanoparticles were fitted with various kinetic equations like zero order, first order 
and Higuchi’smodel, Korsemeyer-peppas and Hixon crowell. 
 
CONCLUSION  
The ultimate aim of the present study was to prepare sustainedrelease matrix tablet of Finasteride 
using hydrophilic polymers like HPMC, EC and Eudragit by wet granulation technique. The 
present research work was successful in improving the efficacy of Finasteride oral therapy as the 
 drug release was extended for ten hours thus reducing dosing frequency thereby improving 
patient compliance. 
The hydrophilic matrix tablet prepared were containing a blend of gel forming polymers. Based 
on different evaluation parameters formulation of batch MT1 is concluded as an optimum 
formulation. 
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